EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Heron Therapeutics's enterprise value is $467.5 Mil.
Heron Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-103.8 Mil. Therefore, Heron Therapeutics's EV-to-EBITDA for today is -4.50.
The historical rank and industry rank for Heron Therapeutics's EV-to-EBITDA or its related term are showing as below:
HRTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.31 Med: -4.95 Max: -1.25
Current: -4.5
During the past 13 years, the highest EV-to-EBITDA of Heron Therapeutics was -1.25. The lowest was -13.31. And the median was -4.95.
HRTX's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.095
vs HRTX: -4.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Heron Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Heron Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Heron Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Heron Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heron Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heron Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Heron Therapeutics's EV-to-EBITDA falls into.
Heron Therapeutics's current Enterprise Value is $467.5 Mil.
Heron Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Heron Therapeutics's PE Ratio for today is calculated as:
Heron Therapeutics's share price for today is $2.50.
Heron Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Heron Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Heron Therapeutics (Heron Therapeutics) Business Description
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HRTX has been successfully added to your 